Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large

Marion Wobser1,2, Andreas Rosenwald2,3, Florian Eisele2,4

  • 1Department of Dermatology, University Hospital Wuerzburg, Germany.

Leukemia & Lymphoma
|May 22, 2026
PubMed
Abstract

No abstract available in PubMed .